Amgen in-licensed KW-0761 monoclonal antibody used for the treatment of cancer and allergy from Kyowa Kakko for US$520 M. The exclusive license covers all regions except Korea, China and Taiwan for which Kyowa Kakko will retain development and commercialization rights.